Hologic (HOLX) Expected to Announce Quarterly Earnings on Wednesday

Hologic (NASDAQ:HOLX) is expected to issue its quarterly earnings data after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $1.01 per share and revenue of $1.03 billion for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company earned $0.89 earnings per share. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $71.77 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $16.20 billion, a price-to-earnings ratio of 21.55, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. Hologic has a twelve month low of $68.61 and a twelve month high of $84.67. The business has a 50 day simple moving average of $73.75 and a 200-day simple moving average of $78.20.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of research reports. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Morgan Stanley decreased their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.